Key Takeaways: Semaglutide is the active ingredient in both Ozempic and Wegovy, working by mimicking GLP-1 to reduce appetite and improve blood sugar control. Wegovy (higher-dose semaglutide) is FDA-approved for weight loss, while Ozempic is primarily approved for type 2 diabetes but often used off-label. Clinical trials show semaglutide can lead to ~15% body weight loss over ~68 weeks when combined with lifestyle changes. Ozempic typically produces slightly lower average weight loss due to its lower maximum dose, though results can still be significant. Gradual tapering off semaglutide, combined with lifestyle support, may help reduce weight regain after stopping treatment. Long-term success depends on pairing medication with nutrition, physical activity, and ongoing medical guidance. Understanding the Basics Semaglutide is the active drug found in both Ozempic and Wegovy

The hERG inhibition data of two analogues of 24 also suggest that the presented chemotype is a good starting point for further lead structure optimization
Do You Need a Prescription for Compounded Semaglutide
Injectable has per-vial cost plus syringes, bacteriostatic water, and alcohol swabs
In a new book, former FDA Commissioner David Kessler aims to go beyond the headlines to take a close look at the science on metabolism, weight loss, and how these new blockbuster drugs actually work
In the absence of specific guidance, a reasonable approach is to take tablets 30-60 minutes before meals